Mer­sana slapped with par­tial FDA hold af­ter five pa­tient deaths in ovar­i­an can­cer stud­ies

An­oth­er one of Mer­sana’s clin­i­cal pro­grams is re­port­ing pa­tient deaths in a study, and now it’s prompt­ing the FDA to step in.

The agency slapped Mer­sana with a par­tial clin­i­cal hold, the biotech an­nounced Thurs­day, halt­ing en­roll­ment in two of three stud­ies for the ovar­i­an can­cer ther­a­py up­i­fi­ta­m­ab ril­sodotin. In­ves­ti­ga­tors ob­served five fa­tal bleed­ing events from 560 pa­tients across all three stud­ies, prompt­ing the hold.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER